These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8326565)

  • 1. Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: a Southwest Oncology Group study.
    Blumenstein B; Crawford ED; Saiers JH; Stephens RL; Rivkin SE; Coltman CA
    J Urol; 1993 Aug; 150(2 Pt 1):411-3. PubMed ID: 8326565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy of hormone-refractory carcinoma of prostate with 5-fluorouracil, adriamycin, and mitomycin C.
    Babaian RJ; Hsu SD
    Urology; 1984 Mar; 23(3):272-5. PubMed ID: 6546626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil.
    Laurie JA; Hahn RG; Therneau TM; Patel SR; Mailliard JA; Windschitl HE; Twito DI; Morton RF; Krook JE
    Cancer; 1992 Mar; 69(6):1440-4. PubMed ID: 1540881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of epirubicin, mitomycin C, and 5-fluorouracil in hormone-refractory prostatic carcinoma.
    Recchia F; Sica G; De Filippis S; Rosselli M; Pompili PL; Rea S
    Am J Clin Oncol; 2001 Jun; 24(3):232-6. PubMed ID: 11404491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma.
    Gibson MK; Holcroft CA; Kvols LK; Haller D
    Oncologist; 2005 Feb; 10(2):132-7. PubMed ID: 15709215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer.
    Logothetis CJ; Samuels ML; von Eschenbach AC; Trindade A; Ogden S; Grant C; Johnson DE
    J Clin Oncol; 1983 Jun; 1(6):368-79. PubMed ID: 6422006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study.
    Hong RL; Sheen TS; Ko JY; Hsu MM; Wang CC; Ting LL
    Br J Cancer; 1999 Aug; 80(12):1962-7. PubMed ID: 10471046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Alternating combination chemotherapy (VIP-DMF) in patients with advanced adenocarcinoma of the prostate].
    Yoshimoto J; Ochi J; Tanahashi T; Nanba K; Saegusa M; Hara M; Akagi T; Obama T; Tsushima T; Ozaki Y
    Gan To Kagaku Ryoho; 1987 Feb; 14(2):434-9. PubMed ID: 2434029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of hormone-resistant metastatic carcinoma of the prostate with 5-FU, doxorubicin, and mitomycin (FAM'): a preliminary report.
    Kasimis BS; Moran EM; Miller JB; Forbes KA; Kaneshiro CA; Poblet MT; Williams JL
    Cancer Treat Rep; 1983 Oct; 67(10):937-9. PubMed ID: 6688755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma. A Southwest Oncology Group study.
    Bukowski RM; Fleming TR; Macdonald JS; Oishi N; Taylor SA; Baker LH
    Cancer; 1993 Jan; 71(2):322-5. PubMed ID: 8422624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclophosphamide versus 5-fluorouracil, doxorubicin, and mitomycin C (FAM') in the treatment of hormone-resistant metastatic carcinoma of the prostate: a preliminary report of a randomized trial.
    Kasimis BS; Miller JB; Kaneshiro CA; Forbes KA; Moran EM; Metter GE
    J Clin Oncol; 1985 Mar; 3(3):385-92. PubMed ID: 3838343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma. A phase II randomized trial of the Italian Oncology Group for Clinical Research.
    De Lisi V; Cocconi G; Angelini F; Cavicchi F; Di Costanzo F; Gilli G; Rodinò C; Soldani M; Tonato M; Finardi C
    Cancer; 1996 Jan; 77(2):245-50. PubMed ID: 8625230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of stage D2 hormone refractory carcinoma of the prostate with 5-fluorouracil and Roferon-A: a Southwest Oncology Group study.
    Marshall ME; Wolf M; O'Rourke M; Barnett TC; Crawford ED
    Cancer Biother Radiopharm; 1996 Apr; 11(2):119-23. PubMed ID: 10851528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer.
    Lise M; Nitti D; Marchet A; Sahmoud T; Buyse M; Duez N; Fiorentino M; Dos Santos JG; Labianca R; Rougier P
    J Clin Oncol; 1995 Nov; 13(11):2757-63. PubMed ID: 7595735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma.
    Koo DH; Lee JL; Kim TW; Chang HM; Ryu MH; Yook JH; Oh ST; Kim BS; Lee JS; Kang YK
    Eur J Surg Oncol; 2007 Sep; 33(7):843-8. PubMed ID: 17207959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin.
    Cullinan S; Moertel CG; Wieand HS; Schutt AJ; Krook JE; Foley JF; Norris BD; Kardinal CG; Tschetter LK; Barlow JF
    Cancer; 1990 May; 65(10):2207-12. PubMed ID: 2189551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OK-432 and 5-fluorouracil, doxorubicin, and mitomycin C (FAM-P) versus FAM chemotherapy in patients with curatively resected gastric carcinoma: a randomized Phase III trial.
    Kim SY; Park HC; Yoon C; Yoon HJ; Choi YM; Cho KS
    Cancer; 1998 Nov; 83(10):2054-9. PubMed ID: 9827708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary.
    Goldberg RM; Smith FP; Ueno W; Ahlgren JD; Schein PS
    J Clin Oncol; 1986 Mar; 4(3):395-9. PubMed ID: 3754004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic chemoembolization combined with systemic infusion of 5-fluorouracil and bolus leucovorin for patients with metastatic colorectal carcinoma: A Southwest Oncology Group pilot trial.
    Leichman CG; Jacobson JR; Modiano M; Daniels JR; Zalupski MM; Doroshow JH; Fletcher WS; Macdonald JS
    Cancer; 1999 Sep; 86(5):775-81. PubMed ID: 10463975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doxorubicin, mitomycin, and 5-FU (DMF) in the treatment of hormone-resistant stage D prostate cancer: a preliminary report.
    Logothetis CJ; von Eschenbach AC; Samuels ML; Trindade A; Johnson DE
    Cancer Treat Rep; 1982 Jan; 66(1):57-63. PubMed ID: 7053267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.